Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
Dr. Bernstein will tap into her decades of leadership and strategy experience as she transitions into this new role at APhA
This agreement is in addition to the $92 million filling line expansion announced in November 2021
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
The life sciences and pharmaceutical sectors suffer from hard-to-source biological materials, which translates into high costs in research and development
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Subscribe To Our Newsletter & Stay Updated
